Outlook Therapeutics to Announce Q2 FY24 Results on May 16, 2024

ISELIN, N.J., May 09, 2024 - Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company, is striving to secure the first approval for an ophthalmic formulation of bevacizumab aimed at treating retinal diseases in both the United States and the European Union. The company has announced that it will disclose its financial results for the second quarter of fiscal year 2024 on Thursday, May 16, 2024. On the same day, they will host their inaugural quarterly conference call along with a live audio webcast to discuss both operational and financial outcomes. This event is scheduled to begin at 8:30 AM ET and will be conducted by Russell Trenary, the President and Chief Executive Officer, along with Lawrence Kenyon, the Chief Financial Officer of Outlook Therapeutics.

For those interested in joining the conference call, domestic participants can dial (877) 407-8291, while international participants should dial (201) 689-8345, referencing the Outlook Therapeutics Conference Call. The live webcast will also be available on the Events page within the Investors section of the Outlook Therapeutics website, outlooktherapeutics.com, and will remain archived for 90 days.

Outlook Therapeutics is actively pursuing FDA and European Commission approval for their product ONS-5010/LYTENAVA™ (bevacizumab-vikg or bevacizumab gamma). This formulation is intended to be the first officially sanctioned ophthalmic version of bevacizumab for use in various retinal conditions such as wet age-related macular degeneration (AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Should the ONS-5010 ophthalmic bevacizumab receive approval, the company anticipates marketing it as the exclusive FDA and/or EC approved ophthalmic bevacizumab formulation for retinal diseases. Their intended market includes not just the United States and the European Union but also extends to the United Kingdom, Europe, Japan, and other regions.

Part of Outlook Therapeutics' comprehensive commercial strategy involves a multi-year plan in collaboration with Cencora. This strategic partnership aims to extend the company's reach to retinal specialists and their patients. Under this agreement, Cencora will be responsible for third-party logistics (3PL) services, distribution, pharmacovigilance, and additional services within the United States.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!